I am deeply passionate about management of DLBCL in patients above age 70 and hope to see more pharma moving in this direction. Seems stunningly foolish to me that fully HALF of all DLBCL cases are virtually ignored in terms of age appropriate therapy trials.
Anyhow, here is my list. Feel free to use the comment section if you think I am missing something really important.
CAR-T therapy in NHL - yet another entity out there that could be called a "game changer" Durability of responses in DLBCL to be key determinant of value
Novel endpoints in FL studies - technical paper about defining a variable you can actually measure in real time to figure out if you are on right track with new approach
R2-CHOP in DLBCL - trial in progress, but I have hopes this will be legitimate change to standard of care. No data yet. Fingers crossed. Going to be a while before this reads out…. like several years. Watch for R-CHOP vs G-CHOP to be first phase III DLBCL study to challenge status quo.
Impact of weight an obesity on rituximab dosing - American love for cheeseburgers killing us with lymphoma
Molecular changes in BCR correlate with ABC vs GCB in DLBCL - nerdy article, but I like it
DLBCL in the elderly - the greatest unmet medical need in lymphoid cancers
More on elderly DLBCL - median age 70, yet such patients rarely on prospective trials
Yet more on elderly DLBCL - any drug company with NHL drug is foolish to ignore the opportunity here
Idelalisib in Waldenstroms - didn't make the FDA label, but still active.
Clearing the junk in amyloid - ok not normally a NHL disease symptom, but this is just too cool